Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 1.04T +55.0% |
| Revenue (ttm) | 369.13B +13.5% |
| Net Income | 39.90B +16.6% |
| EPS | 69.02 +17.1% |
| Shares Out | 575.38M |
| PE Ratio | 26.18 |
| Forward PE | 19.77 |
| Dividend | 7.00 (0.39%) |
| Ex-Dividend Date | Nov 11, 2026 |
| Volume | 2,350,540 |
| Open | 1,813.10 |
| Previous Close | 1,827.50 |
| Day's Range | 1,785.40 - 1,821.10 |
| 52-Week Range | 1,106.00 - 1,859.90 |
| Beta | 0.02 |
| Analysts | Buy |
| Price Target | 1,856.04 (+2.7%) |
| Earnings Date | Nov 4, 2026 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides oi... [Read more]
Financial Performance
In fiscal year 2026, Aurobindo Pharma's revenue was 336.53 billion, an increase of 6.08% compared to the previous year's 317.24 billion. Earnings were 35.05 billion, an increase of 0.54%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for AUROPHARMA stock is "Buy." The 12-month stock price target is ₹1,856, which is an increase of 2.70% from the latest price.
News
Esperion Settles Patent Dispute With Aurobindo, Delays U.S. Generic Competition Until 2040
(RTTNews) - Esperion Therapeutics (ESPR), now wholly owned by ARCHIMED, announced a settlement agreement with Aurobindo Pharma resolving patent litigation related to the cholesterol-lowering medicines...
Aurobindo Pharma Transcript: Q2 26/27
Q2 FY27 revenue rose 24% to a record INR 10,263 crore, while EBITDA grew 28% at a 21% margin. FY27 guidance was reiterated, with Lannett, respiratory launches, China and biosimilars positioned as future growth drivers.
Aurobindo Pharma Quarterly report: Q2 2027
Aurobindo Pharma has published its Q2 2027 quarterly earnings report on November 4, 2026.
Aurobindo Pharma Slides: Q2 2027
Aurobindo Pharma has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
India's Aurobindo Pharma's quarterly profit rises by a third on strong US demand
Indian drugmaker Aurobindo Pharma reported a nearly 33% rise in second-quarter profit on Wednesday, led by strong demand and volume gains in its US market.
Aurobindo Pharma reports 32.5% jump in Q2 net profit to ₹1,124 crore on record revenue from operations
Aurobindo Pharma Q2 net profit jumps 32.5% to ₹1,124 crore as revenue hits record ₹10,263 crore; strong US/Europe growth; ₹7 interim dividend.
Aurobindo arm Apitoria acquires A1 Biochem Labs LLC in $15.25M cash deal
Aurobindo Pharma’s Apitoria acquires US-based A1 Biochem Labs LLC for $15.25M cash, gaining CRO platform with 50+ clients to boost integrated CRDMO.
Aurobindo arm Apitoria gets USFDA observation for Telangana API unit
Aurobindo’s Apitoria API Unit II in Telangana received one procedural USFDA observation; company to respond. Separately, USFDA approved its first generic Qvar inhaler.
Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary
Aurobindo Pharma’s arm Apitoria incorporates Avogent Lifesciences as a new wholly owned India subsidiary; Rs 5 crore cash subscription; pharma manufacturing, marketing.
Aurobindo arm's peptide API unit in Telangana gets 1 USFDA observation
USFDA inspected Aurobindo Pharma subsidiary Auro Peptides’ Telangana peptide API plant (Aug 17–21, 2026) and issued 1 observation on maintenance.
USFDA warns Aurobindo’s Eugia Pharma over sterile drug manufacturing lapses
USFDA issues warning letter to Aurobindo’s Eugia Pharma Unit-I in Telangana for sterile manufacturing lapses, citing contamination control, validation and complaints.
Aurobindo Pharma Transcript: Q1 26/27
Revenue grew 16% year-over-year to INR 9,150 crore, with strong performance across all segments and a 21% EBITDA margin. Lannett acquisition and China facility ramp-up drive U.S. and global growth, while biosimilars and CDMO/CMO businesses show promising outlook.
Aurobindo Pharma Quarterly report: Q1 2027
Aurobindo Pharma has published its Q1 2027 quarterly earnings report on August 5, 2026.
Aurobindo Pharma Slides: Q1 2027
Aurobindo Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s
Laurus Labs hits Rs 1 lakh crore market cap as shares rally 115% in a year, overtaking Dr Reddy’s and Aurobindo; Divi’s crosses Rs 2.2 lakh crore.
India's Aurobindo Pharma posts quarterly profit rise on anti-retroviral drug demand
Indian drugmaker Aurobindo Pharma reported a 25.2% rise in quarterly profit on Wednesday, driven by steady domestic demand, especially for its anti-retroviral drugs used to treat HIV infections.
Revanth plans farm-to-school link for govt breakfast scheme
Telangana CM Revanth Reddy proposes direct procurement of organic produce from local farmers for govt school meals; Aurobindo, Divi’s donate ₹22.18 crore.
Aurobindo arm CuraTeQ gets Brazil regulator ANVISA nod for Hyderabad biosimilars facility
CuraTeQ Biologics, Aurobindo’s arm, wins ANVISA approval for its Hyderabad biosimilars plant after GMP inspection, supporting Brazil and Latin America supply.
Pharma sector stocks surge today, July 3: Aurobindo Pharma jumps 2.74%, Sudeep Pharma gains 2.43%, Lupin up 1.95%
Indian pharma sector stocks displayed a mixed but largely positive trend in early trading, as of 9:47 AM IST. The S&P BSE Healthcare index rose 1.03% to reach 49,951.86 points.…
Aurobindo Pharma completes transfer of domestic branded generics to subsidiary
Aurobindo Pharma has finalised the transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited. The transfer, effective from 1 July ...
Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41%
The pharma sector showed mixed movement on June 30, 2026, during morning trade. The BSE Healthcare index was up 0.15% at 49,094.24, while the broader market indices remained in negative…
Aurobindo Pharma completes acquisition of Lannett Company
Aurobindo Pharma USA Inc. (APUSA), a wholly owned subsidiary of Aurobindo Pharma, has successfully completed its acquisition of Lannett Company, Inc., USA, from Lannett Seller Holdco, Inc. This follow...
Aurobindo Pharma's subsidiary faces two US FDA observations after inspection
The United States Food and Drug Administration (US FDA) recently concluded an inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, with two observations. The...
Aurobindo Pharma completes solar power agreement with Rs 52 lakh investment
Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited. The company made an initial investment of…
Aurobindo gets US FTC nod to acquire Lannett Co for $250 million
Aurobindo Pharma USA wins FTC approval to buy Lannett for $250M, boosting complex generics and US manufacturing capacity; deal to close by June 2026.